Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Dilution Analysis

10-Q filing | 18.7M shares outstanding

10-K filing | 17.7M shares outstanding

10-Q filing | 17.6M shares outstanding

8-K filing: Corbus Pharmaceuticals Holdings, Inc. entered into an underwriting agreement for a public offering of 4,744,231 shares of common stock at $13.00 per share and pre-funded warrants to purchase up to 1,025,000 shares of common stock at $12.9999 per share. ($75.0M proceeds)

10-Q filing | 12.2M shares outstanding

10-K filing | 12.2M shares outstanding

10-Q filing | 12.0M shares outstanding

8-K filing: John Jenkins M.D., a director of Corbus Pharmaceuticals Holdings, Inc., adopted a Rule 10b5-1 plan to sell up to 5,436 shares of the Company's common stock beginning on November 30, 2024, and terminating on November 29, 2025.

10-Q filing | 11.1M shares outstanding

8-K filing: On June 14, 2024, Yong Ben M.D., a board member of Corbus Pharmaceuticals Holdings, Inc., adopted a Rule 10b5-1 plan for the potential sale of up to 10,607 shares of the company's common stock starting on September 12, 2024, and terminating on September 11, 2025.

10-Q filing | 10.7M shares outstanding

8-K filing: Dr. Cohen and Mr. Moran, officers of Corbus Pharmaceuticals Holdings, Inc., adopted Rule 10b5-1 plans to sell up to 117,066 and 42,606 shares of the company's common stock, respectively, beginning on June 13, 2024.

S-3 filing: Corbus Pharmaceuticals Holdings, Inc. is offering common stock, preferred stock, debt securities, subscription rights, and units up to an aggregate public offering price of $300,000,000.

10-K filing | 10.5M shares outstanding

8-K filing: Corbus Pharmaceuticals Holdings, Inc. completed an underwritten public offering of 4,325,000 shares of common stock, with the underwriters exercising their option to purchase an additional 648,750 shares, at a price of $19.00 per share, resulting in expected net proceeds of approximately $88.5 million. ($0.0M proceeds)

10-Q filing | 4.4M shares outstanding

10-Q filing | 4.3M shares outstanding

S-3/A filing: Corbus Pharmaceuticals Holdings, Inc. is offering various securities, including common stock, preferred stock, debt securities, subscription rights, and units, with an aggregate public offering price not exceeding $100,000,000. They are also offering common stock through an "at-the-market" offering for up to $16,800,000 through Jefferies LLC.

S-3 filing: Corbus Pharmaceuticals Holdings, Inc. is offering common stock, preferred stock, debt securities, and subscription rights with an aggregate public offering price not to exceed $100,000,000. The company intends to use the net proceeds from this offering to fund the continued development of CRB-701, CRB-601, and its other pre-clinical compounds as well as for general corporate purposes.

10-Q filing | 4.2M shares outstanding

10-K filing | 4.2M shares outstanding

8-K filing: Stock split 1-for-30 | Outstanding: 125,268,381 → 4,176,029

10-Q filing | 125.3M shares outstanding

8-K filing: Corbus Pharmaceuticals Holdings, Inc. amended its Loan and Security Agreement, adjusting the conversion price for a portion of the convertible debt; $875,000 of the loan will be converted at $0.15 per share, and $1,125,000 of the loan at $0.2625 per share.

10-Q filing | 125.3M shares outstanding

10-Q filing | 125.2M shares outstanding

10-K filing | 123.0M shares outstanding

10-Q filing | 125.2M shares outstanding

10-Q filing | 116.4M shares outstanding

8-K filing: Corbus Pharmaceuticals Holdings, Inc. entered into an Exclusive License Agreement with The Regents of the University of California and a License Agreement with Milky Way BioPharma, LLC, and agreed to issue 147,875 shares of common stock to Milky Way.

10-Q filing | 125.0M shares outstanding

10-K filing | 124.9M shares outstanding

10-Q filing | 84.0M shares outstanding

10-Q filing | 81.7M shares outstanding

8-K filing: Corbus Pharmaceuticals entered into a Loan and Security Agreement providing for term loans up to $50,000,000 and issued a warrant to purchase up to 86,206 shares of common stock at an exercise price of $6.96 per share in connection with the initial tranche.

10-Q filing | 72.5M shares outstanding

S-3/A filing: Corbus Pharmaceuticals Holdings, Inc. is offering a combination of common stock, preferred stock, warrants, senior or subordinated debt securities, subscription rights and units, with an aggregate public offering price not to exceed $200,000,000.

S-3 filing: Corbus Pharmaceuticals Holdings, Inc. is offering common stock, preferred stock, debt securities, subscription rights, and units for an aggregate public offering price not to exceed $200,000,000.

10-K filing | 72.5M shares outstanding

8-K filing: Corbus Pharmaceuticals Holdings, Inc. entered into an underwriting agreement for the offering, issuance, and sale of 6,666,667 shares of its common stock at a price of $6.00 per share, with net proceeds expected to be approximately $37,350,000. Underwriters have an option to purchase up to 1,000,000 additional shares. ($37.35M proceeds)